Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2007-04-25 | Rodney S. Markin, M.D., Ph.D. . 50 President and CEO of University of Nebraska Medical Center Physicians. The Audit Committee current members include Markin. The Compensation Committee currently consists of directors Sklar, Duman, and Markin. No 2006 compensation is reported for Rodney Markin since he joined the Board in 2007. |
| 2008-04-23 | Rodney S. Markin, M.D., Ph.D. Age 51 Chairman of the Board, Transgenomic, Inc President and CEO of University of Nebraska Medical Center Physicians Director since 2007 Audit Committee member Compensation Committee member Director compensation total $17,570 in 2007. |
| 2009-04-21 | The Board of Directors has nominated Dr. Rodney Markin as a Class III director to serve a three-year term expiring in 2012. Dr. Markin is a currently Chairman of the Board of Directors. The Audit Committee current members are directors Markin, Duman and Sloma. The Compensation Committee currently consists of directors Sklar, Witney, Duman and Markin. Director compensation table shows Rodney Markin with total compensation of $30,381. |
| 2010-04-19 | Rodney S. Markin, M.D., Ph.D. 53 Chairman of the Board, Transgenomic, Inc. President of University of Nebraska Medical Center Physicians The Audit Committee current members are directors Sloma, Markin and McNulty. The Compensation Committee currently consists of directors Markin, Sklar and Schuh. Director Compensation Table shows Rodney Markin received $28,000 in fees and $1,749 in option awards totaling $29,749. |
| 2011-04-18 | Rodney Markin Age: 54 Chairman of the Board, Transgenomic, Inc. President of University of Nebraska Medical Center Physicians Director since 2007, term to expire 2012. Compensation: $26,500 fees earned or paid in cash, $2,065 option awards, total $28,565. Audit Committee and Compensation Committee member. Excerpt: "Rodney Markin 26,500 2,065 28,565 ... The Audit Committee current members are Koppler, Markin and Patzig. The Compensation Committee currently consists of directors Schuh, Markin and Patzig..." |
| 2013-04-25 | Rodney S. Markin, M.D., Ph.D., Common Stock Director, Age 56, Chairman of the Board, Transgenomic, Inc., Chief Technology Officer, University of Nebraska Medical Center, Director Since 2007, Term to Expire 2015. Chairman of the Board. Member of Audit Committee and Compensation Committee. Director Summary Compensation Table shows $31,625 fees earned in cash and $32,127 option awards totaling $63,752. |
| 2013-12-24 | Rodney S. Markin, M.D., Ph.D., Director. Includes 80,000 shares issuable upon the exercise of options. Compensation table shows $70,716 grant date fair value of awards. |
Data sourced from SEC filings. Last updated: 2026-03-05